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Background: Aberrant methylation patterns in CpG island are known to be influential in gene silencing. Histamine
plays important physiological roles in the upper gastrointestinal tract and acts via the H2 receptor. We report an
investigation into the effect of HRH2 promoter polymorphism (rs2607474 G > A) on the methylation of DAPK and
CDH1.
Methods: Non cancerous gastric mucosa samples were obtained from 115 subjects with gastric cancer (GC) and
412 non-cancer subjects (non-GC). Methylation status of genes was determined by MSP. The genotyping of
rs2607474 was performed by PCR-SSCP.
Results: Methylation of DAPK and CDH1 was observed in 296 and 246 subjects, respectively. The frequency of CDH1
methylation in the subjects with GC was significantly lower in cancer lesion than in non cancerous mucosa,
whereas that of DAPK methylation was not different. The allelic distribution of rs2607474 was 401GG, 119GA and
7AA. The GG homozygote was associated with a significantly increased risk for methylation of both DAPK and CDH1
(p < 0.0001 and p = 0.0009, respectively). In the non-GC subjects or more than 60 years of age, GG homozygote was
more closely associated with both DAPK and CDH1 methylation. However, this genotype did not show an increased
risk for the development of methylation of both genes in patients with GC. In H. pylori negative subjects, GG
homozygote showed an increased risk for the methylation of both DAPK and CDH1 (p = 0.0074 and p = 0.0016,
respectively), whereas this genotype was associated with an increased risk for the development of DAPK
methylation in H. pylori positive subjects (p = 0.0018). In addition, in subjects older than 60 years of age, atrophy
and metaplasia scores were significantly higher in the GG homozygote (p = 0.011 and p = 0.039, respectively) and a
significant correlation was observed between age and atrophy or metaplasia.
Conclusions: Our results suggest that rs2607474 GG homozygote confers a significantly increased risk for age- and
inflammation-related DAPK and CDH1 methylation.
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Gastric cancer is one of the most common cancers
worldwide and is associated with a high mortality rate
[1,2]. Several cancers, including gastric tumors, show
methylation of multiple genes including E-cadherin
(CDH1), death-associated protein kinase (DAPK) and
cyclin-dependent kinase inhibitor 2A (CDKN2A) [3,4].
Methylation of promoter CpG islands leads to DNA
structural changes and, consequentially, gene inactiva-
tion [5]. Many studies have identified this silencing by
DNA methylation as a mechanism responsible for tumor
suppressor inactivation. However, some genes are also
methylated in non-neoplastic tissues due to ageing [6,7],
and it has also been suggested that gene methylation
occurs during chronic inflammation in various tissues
[8-10]. In gastric mucosa, it has been postulated that
methylation of CpG island is induced by Helicobacter
pylori (H. pylori) infection in non-cancerous mucosa
[11,12] and considered as the precancerous conditions
in gastric carcinogenesis [13]. Among several genes,
DAPK, CDH1and CDKN2A are known to be frequently
methylated in non-neoplastic gastric mucosa and this
methylation is linked to age, H. pylori infection, histo-
logical degree of gastritis, and gastric cancer [11,13,14].
However, histamine, one of the active amines released
in response to a variety of physiological stimuli, is widely
distributed in the gastrointestinal tract including the
stomach and is involved in the pathogenesis of gastro-
duodenal ulceration and gastric inflammation [15]. In
the stomach, H2 receptors, although widely distributed
in body tissues, seem to have a central role in the regula-
tion of acid secretion, as confirmed by the widespread
use of H2 receptor blockers in the therapy of acid-
related disorders [16,17]. Histamine plays an important
role in gastric inflammation acting via the H2 receptor,
although H. pylori infection is one of the major contrib-
uting factors to the development of gastro-duodenal
inflammation [18]. Recently, the association between
genetic polymorphisms of histamine receptor genes and
susceptibility to schizophrenia, and its clinical response
to clozapine treatment has been studied [19]. This inves-
tigation of the polymorphisms of HRH2, coding for the
H2 receptor, reveals association between the genotype at
the HRH2 -1018 G/A locus (rs2607474) and clinical re-
sponse to clozapine treatment. In addition, this report
has shown that rs2607474 is located in an enhancer
element of the HRH2 gene promoter [19,20] and it is
thus likely that this variant induces changes in the ex-
pression of receptors. According to HapMap-JPT, there
is only one linkage disequilibrium (LD) block, composed
of rs686874, rs2067474, rs678591, rs645574, rs2890892
and rs11954815, in HRH2. All the other SNPs are minor
polymorphisms. Therefore, we speculated that this LD
block influence the expression and/or function ofhistamine H2 receptor and selected rs2607474 as a Tag
SNP. There has not yet been any report on the
rs2607474 affect on the development and progression of
gastrointestinal disorders. We hypothesized that the
rs2607474 may influence the development of aberrant
DNA methylation patterns in gastric mucosa.
In the present study, we investigated the relationship
between HRH2 promoter polymorphism (rs2607474)
and DNA methylation of DAPK and CDH1 in non-
cancerous gastric epithelium. The difference of DNA
methylation status among gastric cancer patients and
non-cancerous subjects was also investigated.
Methods
Tissue samples, DNA extraction, and helicobacter pylori
infection status
Our studied population comprised 527 subjects (412
without malignant tumors and 115 with gastric cancer)
recruited from the Endoscopy Center of Fujita Health
University Hospital or Kanazawa Medical University
Hospital. Patients with systemic severe diseases were
excluded from this study. Those with active gastric or
duodenal ulcers were also excluded. All subjects under-
went upper endoscopy with biopsy from non-cancerous
mucosa. In 115 subjects with gastric cancer, biopsy spe-
cimen was also obtained from cancer lesion. Parts of
each specimen were immediately frozen and stored at
−80°C, while some of the other part was fixed in 10%
buffered formalin and embedded in paraffin. Later, Gen-
omic DNA was extracted directly from frozen specimens
using standard phenol/chloroform method after protein-
ase K digestion. In 296 of 412 subjects without gastric
cancer, the severity of chronic gastritis was classified
according to the updated Sydney system [21] by a path-
ologist who had no access to any clinical information. H.
pylori infection status was assessed by serology, hist-
ology, or urea breath test. Subjects were diagnosed as
infected when at least one of the diagnostic tests was
positive.
The Ethics Committees of the Fujita Health University
and Kanazawa Medical University approved the proto-
col, and prior, written informed consent was obtained
from all participating subjects.
Bisulfite modification and methylation-specific PCR (MSP)
To examine DNA methylation, genomic DNA was treated
with sodium bisulfite using BislFast DNA Modification
Kit for Methylated DNA Detection (TOYOBO, Co., Ltd.,
Osaka, Japan). MSP for DAPK and CDH1 were carried
out using the methods reported by Katzenellenbogen et al.
[22] and Herman et al. [23], respectively.
In brief, MSP reactions were carried out with the
following primer pairs using EX Taq HS (Takara Bio,
Inc., Shiga, Japan).
Table 1 Characteristics of the subjects and frequencies of
gene methylation
Overall non-GC GC p value*
the number of subjects 527 412 115
mean age ± SD 61.0 ± 13.7 60.0 ± 13.8 66.2 ± 9.7 0.0019
male : female 319 : 208 235 : 177 84:31 0.0018
H.pylori positive ratio 338/527 249/412 89/115 0.00091
DAPK methylated ratio 296/527 201/412 95/115 <0.0001
CDH1 methylated ratio 246/527 150/412 96/115 <0.0001
*: non-GC group vs. GC group.
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DAPK: methylated forward; 50- ggatagtcggatcgagttaacgtc-30
reverse; 50- ccctcccaaacgccga-30,
DAPK: unmethylated forward; 50- ggaggatagttggattgagt-
taatgtt-30,
reverse; 50- caaatccctcccaaacaccaa-30,
CDH1: methylated forward; 50- ttaggttagagggttatcgcgt-30,
reverse; 50- taactaaaaattcacctaccgac-30,
CDH1: unmethylated forward; 50- taattttaggttagagggt-
tattgt-30,
reverse; 50- cacaaccaatcaacaacaca-30,
Annealing temperature and times were determined
using DNA from peripheral blood of a young individual
without H. pylori infection as a negative control and this
DNA methylated with SssI methylase (NEW ENGLAND
BioLabs Inc., Beverly, MA) as a positive control. The
MSP was carried out in a volume of 20μL containing
0.1 μg of bisulfite-modificated DNA. The DNA was
denatured at 95°C for 5 minutes, followed by 35 cycles
at 95°C for 30 seconds, 64 or 65°C (for CDH1 or DAPK,
respectively) for 1 minutes, and 72°C for 1 minute with
a final extension at 72°C for 5 minutes. The bands of
MSP were detected by electrophoresis in 3.0% agarose
gels stained with ethdium bromide. Hypermethylation
was defined as the presence of a positive methylation
band showing signals approximately equal to or greater
than that of the size marker (10 ng/μL: 100 bp DNA
Ladder, Takara Bio, Inc., Shiga, Japan) regardless of the
presence of unmethylated bands [4].
Genotyping of HRH2 polymorphism
The rs2607474 was genotyped by PCR-SSCP as reported
previously [24,25]. To detect the genotype, using the pri-
mer pair (forward: 50-acctgacccttttctgaaaaagtttgtc-30, and
reverse: 50-ctactcctctgaagtgctgagaaccat-30), PCR was car-
ried out in a volume of 20 μL containing 0.1 μg of gen-
omic DNA. The DNA was denatured at 95°C for
3 minutes, followed by 35 cycles at 96°C for 15 seconds,
60°C for 30 seconds, and 72°C for 30 seconds, with final
extension at 72°C for 5 minutes. Thereafter, 2 μL of PCR
product was denatured with 10 μL of formamide (Sigma-
Aldrich Co., St. Louis, USA) at 95°C for 5 minutes. SSCP
was carried out at 6°C using a GenePhor DNA separation
system with GeneGel Excel 12.5/24 (GE Healthcare,
USA), after which the denatured single strand DNA bands
were detected using a DNA Silver Staining Kit (GE
Healthcare). We confirmed that single strand DNAs were
clearly separated by this condition [25]. SSCP results were
confirmed using positive DNA fragments prepared by
nested-PCR as reported previously [24,26].Statistical analysis
Age and updated Sydney system scores were expressed
as mean ± SD. Mean ages between two groups were
compared with Student’s t test. The ratio of gender, H.
pylori infection and DNA methylation were compared
using Fisher’s exact test. The allele counts were also
compared between the methylated and the unmethylated
groups by Fisher’s exact test. Adjusted ORs were calcu-
lated with the use of logistical regression analysis after
adjustment for age, gender and H. pylori infection status.
Each updated Sydney system scores among 2 groups was
compared by Mann Whitney U-test. The correlation be-
tween age and each updated Sydney system score was
assessed by ANOVA. For all analyses, the level of signifi-
cance was set at p < 0.05.
Results
Subjects
A total of 412 non-cancer (non-GC) subjects and 115
gastric cancer (GC) patients participated in this study.
These characteristics are summarized in Table 1. The
mean age and male/female ratio of the GC group were
significantly higher than those in the non-GC group.
The H. pylori positive ratio of the GC group was also
significantly higher than that of the non-GC group. Fur-
thermore, the frequencies of CpG methylation of both
DAPK and CDH1 were significantly higher in the GC
group than in the non-GC group.
Frequencies of rs2607474 genotypes among DAPK
methylated and unmethylated groups
The distribution of this genotype in all 527 subjects was
401GG, 119GA and 7AA and was in Hardy-Weinberg
equilibrium (p = 0.70). The mean age, H. pylori positive
ratio and GC/non-GC ratio were significantly higher in
the DAPK methylated than in the unmethylated groups,
whereas the male/female ratio among the two groups
was not significantly different (Table 2). The minor allele
frequency of rs2607474 in the methylated group was
significantly lower than that in the unmethylated group
(p < 0.0001, setting α = 0.05, 1-βpower = 0.978). In addition,
the frequency of the GG homozygote was significantly
Table 3 The frequencies of genotypes among CDH1










mean age ± SD 60.6 ± 14.0 61.4 ± 13.3 NS
male : female 165 : 116 154 : 92 NS
H. pylori positivity 152/281 186/246 <0.0001
non-GC : GC 262 : 19 150 : 96 <0.0001
HRH2 rs2607474 genotype
G/G 197 204 0.013#
G/A 78 41
A/A 6 1
A allele frequency 16.0% 8.7% 0.0004
*: unmethylated vs. methylated, #: frequency of GG homozygote.
NS: not significant.
Nomura et al. BMC Gastroenterology 2013, 13:1 Page 4 of 9
http://www.biomedcentral.com/1471-230X/13/1higher in the methylated group than in the unmethylated
group (p < 0.0001).
Frequencies of rs2607474 genotypes among CDH1
methylated and unmethylated groups
The H. pylori positive ratio and GC/non-GC ratio were
significantly higher in the CDH1 methylated group than
in the unmethylated group, whereas mean age and male/
female ratio among the two groups were not signifi-
cantly different (Table 3). The minor allele frequency of
rs2607474 in the methylated group was significantly
lower than that in the unmethylated group (p = 0.0004,
setting α = 0.05, 1-βpower = 0.946) and the frequency of
the GG homozygote was significantly higher in the methy-
lated group than in the unmethylated group (p = 0.013).
Risk associated with rs2607474 GG homozygote for DAPK
and CDH1 methylation
Overall, rs2607474 GG homozygote conferred a highly
significant increased risk for the development of DAPK
methylation (OR, 2.43; 95%CI, 1.60-3.69; p < 0.0001;
Table 4). In the non-GC subjects, the GG homozygote
also showed a significantly increased risk for the develop-
ment of DAPK methylation (OR, 2.61; 95%CI, 1.62-4.20;
p < 0.0001). However, it displayed neither a significant risk
in non cancerous mucosa nor in cancer lesion in subjects
with GC (Table 4). The frequency of DAPK methylation
was not significant different between non cancerous mu-
cosa and cancer lesion in subjects with GC (95/115 vs.
104/115, p = 0.12).
On the other hand, rs2607474 GG homozygote was
associated with a significantly increased risk for the
development of CDH1, as well as DAPK, methylation
(OR, 2.07; 95%CI, 1.35-3.17; p = 0.0009; Table 5). In the
non-GC subjects, the GG homozygote was alsoTable 2 The frequencies of genotypes among DAPK










mean age ± SD 59.6 ± 13.4 62.1 ± 13.8 0.035
male : female 137 : 94 182 : 114 NS
H. pylori positivity 122/231 216/296 <0.0001
non-GC : GC 211 : 20 201 : 95 <0.0001
HRH2 rs2607474 genotype
GG 155 246 <0.0001#
GA 72 47
AA 4 3
A allele frequency 17.3% 9.0% <0.0001
*: unmethylated vs. methylated, #: frequency of GG homozygote.
NS: not significant.associated with a significantly increased risk for the de-
velopment of CDH1 methylation (OR, 2.25; 95%CI, 1.35-
3.75; p = 0.0019). However, it exhibited neither a signifi-
cant risk in non cancerous mucosa nor in cancer lesion
in subjects with GC (Table 5). The frequency of CDH1
methylation in the subjects with GC was significantly
lower in cancer lesion than in non cancerous mucosa
(78/115 vs. 96/115, p = 0.009).
Risk associated with rs2607474 GG homozygotes for the
development of DNA methylation in subjects above and
below 60 years of age
In subjects younger than 60 years of age, rs2607474
GG homozygote conferred a slightly, but significantly,
increased risk for DAPK methylation (OR, 2.12; 95%CI,
1.13-3.98; p = 0.020, Table 6), whereas not for CDH1
methylation. However, the GG homozygote showed a
significantly increased risk for the development of both
DAPK and CDH1 methylation in subjects older than
60 years (OR, 2.72; 95%CI, 1.55-4.80; p = 0.0005 and
OR, 2.81; 95%CI, 1.53-5.17; p = 0.0009, respectively,
Table 6).
Risk associated with rs2607474 GG homozygotes for the
development of DNA methylation in H. pylori negative or
positive subjects
In H. pylori negative subjects, rs2607474 GG genotype
was associated with an increased risk for the methylation
of both DAPK and CDH1 (OR, 2.70; 95%CI, 1.31-5.57;
p = 0.0074, and OR, 4.43; 95%CI, 1.76-11.1; p = 0.0016, re-
spectively, Table 7). However, the GG homozygote dis-
played an increased risk for the development of DAPK
methylation in H. pylori positive subjects (OR, 2.29; 95%
CI, 1.36-3.86; p = 0.0018), but not for CDH1 methylation.
Table 4 Risk of −1018 GG homozygote for the development of DAPK methylation
Overall (527) GG GA AA GG vs A carrier; OR (95%C.I.) p value
unmethylated (231) 155 72 4 reference -
methylated (296) 246 47 3 2.43 (1.60-3.69) <0.0001
non-GC (412)
unmethylated (211) 138 69 4 reference -
methylated (201) 167 31 3 2.61 (1.62-4.20) <0.0001
GC (115)
(non cancerous mucosa)
unmethylated (20) 17 3 0 reference -
methylated (95) 79 16 0 0.825 (0.379-3.73) 0.78
(cancer lesion)
unmethylated (11) 10 1 0 reference -
methylated (104) 86 18 0 0.598 (0.069-5.19) 0.64
by logistic regression analysis after adjustment for age, gender and H. pylori infection status.
(): the number of subjects.
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rs2607474
Overall, there were no significant differences in atrophy or
metaplasia scores between the GG homozygote and the
GA+AA genotype (Figure 1). However, in subjects older
than 60 years of age, both scores were significantly higher
in the GG homozygote than in the GA+AA genotype.
Both atrophy and metaplasia scores were strongly cor-
related with age in the GG homozygote (both p < 0.0001
by ANOVA, Figure 2a, b), whereas there was no such
correlation between age and either score in the GA+AA
genotype (p = 0.76 and p = 0.69, respectively, Figure 2c, d).
Discussion
We have previously reported that CpG island methyla-
tion of both DAPK and CDH1, in non-neoplastic gastricTable 5 Risk of −1018 GG homozygote for the development o
Overall (527) GG GA
unmethylated (281) 197 78
methylated (246) 204 41
non-GC (412)
unmethylated (262) 180 76
methylated (150) 125 24
GC (115)
(non cancerous mucosa)
unmethylated (19) 17 2
methylated (96) 79 17
(cancer lesion)
unmethylated (37) 30 7
methylated (78) 66 12
by logistic regression analysis after adjustment for age, gender and H. pylori infecti
(): the number of subject.mucosa, corresponded to an increased risk of gastric can-
cer [4]. In the present study, the frequency of methylation
in both genes was significantly higher in the subjects with
GC than without GC. However, the frequency of CDH1
methylation in cancer lesion was significantly lower than
that in non cancerous mucosa in the subjects with GC, al-
though the frequency of DAPK methylation was not. From
these findings, CDH1 methylation seems to take little part
in the development of gastric cancer. In our studied sub-
jects, gene methylation may not reflect the expression of
protein or mRNA, although some previous studies dem-
onstrate that these gene methylations contribute to de-
creasing levels of protein and mRNA [27-30]. Another
possibility is that tumor may develop through E-cadherin
independent pathways for carcinogenesis. The mechanism
of carcinogenesis via gene methylation is still unclear.f CDH1 methylation
AA GG vs A carrier; OR (95%C.I.) p value
6 reference -
1 2.07 (1.35-3.17) 0.0009
6 reference -
1 2.25 (1.35-3.75) 0.0019
0 reference -
0 0.579 (0.120-2.80) 0.50
0 reference -
0 1.50 (0.507-4.42) 0.47
on status.
Table 6 Risk of rs2697474 GG homozygote in younger or
older subjects
DAPK methylation




80 32 3 reference -




75 40 1 reference -
methylated (178) 150 26 2 2.72 (1.55-4.80) 0.0005
CDH1 methylation






88 29 4 reference -




109 49 2 reference -
methylated (134) 116 17 1 2.81 (1.53-5.17) 0.0009
by logistic regression analysis after adjustment for age, gender and H. pylori
infection status.
(): the number of subjects.
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of gene methylation actually shows an increased risk of
carcinogenesis as many studies have indicated [3,4,6,7,11-
14,31,32], even if methylation of CDH1 may not directly
affect the tumor development.Table 7 Risk of rs2607474 GG homozygote in H. pylori








unmethylated (109) 73 35 1 reference -
methylated (80) 67 12 1 2.70 (1.31-5.57) 0.0074
H. pylori positive (338)
unmethylated (122) 82 37 3 reference -








unmethylated (129) 86 41 2 reference -
methylated (60) 54 6 0 4.43 (1.76-11.1) 0.0016
H. pylori positive
(338)
unmethylated (152) 111 37 4 reference -
methylated (186) 150 35 1 1.50 (0.900-2.51) 0.12
by logistic regression analysis after adjustment for age and gender.
(): the number of subjects.There are few reports that demonstrate an influence of
polymorphisms of HRH2 on the risk for human disor-
ders, but those there are report no association between
rs2607474 and neurological or psychological disorders,
such as schizophrenia or Parkinson’s disease [19,20,33].
We are unaware of any previous reports on the associ-
ation between this polymorphism and gastric disorders.
In the present study, we investigated the association be-
tween rs2607474 and the developments of CpG island
methylation of both DAPK and CDH1 in non-cancerous
gastric mucosa. Our current study reveals that rs2607474
GG genotype was positively associated with the develop-
ment of CpG island methylation of both genes. In
addition, we also reveal that gastric mucosal atrophy is
more severe in comparatively older GG homozygote than
GA+AA genotype, and that gastric mucosal atrophy pro-
gresses with age only in GG homozygote.
One of the most important factors causing gene methy-
lation in the stomach is H. pylori infection [4]. Infection
with H. pylori first induces chronic superficial gastritis,
which can progress to chronic atrophic gastritis, intestinal
metaplasia, and dysplasia that can lead gastric carcinoma
[34]. The factors promoting H. pylori-mediated gastric
atrophy are somewhat more controversial. H. pylori infec-
tion results in an elevation of serum gastrin level, in the
early stage of infection, and proceeds to the development
of atrophic gastritis. The majority of clinical studies, how-
ever, have accepted that proton pump inhibitors (PPIs),
which induce achlorhydria and hypergastrinemia, acceler-
ate the onset of atrophic gastritis in H. pylori positive
patients [35-37]. Therefore, hypergastrinemia seems to
promote the gastric mucosal atrophy that is influenced by
H. pylori infection. Interstingly, long-term treatment of
rats and mice with loxtidine, a potent H2 receptor antago-
nists inducing ECL cell hyperplasia, (as does omeprazole),
did not result in loss of parietal cells, but instead appeared
to result in increased parietal cells [38,39]. In addition,
HDC knockout mice kept on a low-histamine diet showed
an expanded parietal cell pool despite exhibiting marked
hypergastrinemia [40]. These results suggest that it is the
up-regulation of histamine, not achlorhydria nor hyper-
gastrinemia, that contributes to the gradual down-
regulation of parietal cell number and gastric atrophy. In
our present study, gastric mucosal atrophy progressed
with age in rs2607474 GG homozygote cohort, whilst in
the GA+AA genotype it did not. In addition, the degree
of gastric mucosal atrophy was higher in older subjects
who were the GG homozygote than in those that were
the GA + AA genotype. In our previous study, a correl-
ation between intestinal metaplasia and gene methyla-
tion of various genes has been confirmed [4]. We
therefore suggest that gene methylation progresses
more rapidly in parallel with gastric mucosal atrophy in
the GG homozygote than in the GA + AA genotype.
Figure 1 Comparisons of Sydney system scores among GG homozygote and GA + AA genotype. Overall, neither atrophy nor metaplasia
scores were significantly different among GG homozygote and GA + AA genotype. However, in the subjects older than 60 years, both scores
were significantly higher in GG homozygote than in GA + AA genotype.
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is up-regulated in GG homozygote. However, there have
been no studies for the effects of rs2607474 on function
or expression of H2 receptors and our genetic statistical
study did not reveal them. This is one of the limitations
in our study. Further study using other methods and
other techniques are necessary to evaluate the function
of rs2607474.Figure 2 Association between rs2607474 and gastric mucosal atroph
Atrophy score was significantly correlated to the age (p = 0.0001 by ANOVA, n
homozygote Metaplasia score was significantly correlated to the age (p < 0.00
genotype. There was no significant correlation (p = 0.47 by ANOVA, n = 63). d
There was no significant correlation (p = 0.48 by ANOVA).It has been recently reported that GC patients show
higher frequencies of aberrant CpG island methylation
in non neoplastic mucosa than non-GC subjects [32]. In
our present study, the frequencies of DAPK and CDH1
methylation were also significantly higher in subjects
with GC than without GC. On the other hand, rs2607474
GG homozygote was associated with a significantly
increased risk for both DAPK and CDH1 methylation iny. a: Correlation between age and atrophy score in GG homozygote
= 233). b: Correlation between age and metaplasia score in GG
01 by ANOVA). c: Correlation between age and atrophy score in GA+ AA
: Correlation between age and metaplasia score in GA+ AA genotype.
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GC. The methylation frequency of DAPK and CDH1 was
higher in GC patients than in non-GC cases, and there
were few GC patients without methylation of DAPK and
CDH1 (20/115 and 19/115, respectively). That is, almost
all GC patients have non-cancerous gastric mucosa in
which some genes are already methylated. In addition, the
cohort composed of only GC patient may have a certain
kind of bias. Therefore, the influence of HRH2 genotype
on methylation status of non-cancerous mucosa in
patients who have already developed gastric cancer may
be indistinct.
A significantly increased risk of the GG homozygote
for DAPK methylation was seen regardless of the age or
H. pylori infection status, whilst that for CDH1 was not
seen in the comparatively younger subjects or H. pylori
positive subjects. Why such a difference was seen is un-
known. The mechanisms which ageing or inflammation
influences methylation are unclear. We demonstrated in
this study that, in the GG homozygote, gastric mucosal
atrophy was correlatively progressed with age and was
more severe in the comparatively older subjects. As for
one possibility, it might be hard for CDH1 methylation
to undertake the influence of ageing or inflammation
than DAPK methylation.
Conclusions
3In conclusions, the HRH2 promoter polymorphism
rs2607474 influences the methylation status of DAPK
and CDH1. These findings are observed in non-GC sub-
jects, not in GC patients. The rs2275913 GG homozy-
gote confers a significantly increased risk for age- and
inflammation-related gene methylation of both genes.
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